Coloplast AS - ADR

Q1 Performance and Guidance: Coloplast reported 6% organic revenue growth in Q1 2025-2026, with an EBIT growth of 3% in constant currencies. The company maintains its full-year organic growth guidance of approximately 7%, but has reduced expectations for Kerecis growth to 10% due to market uncertainties following Medicare reimbursement changes, while increasing outlook for Interventional Urology to high single digits due to a strong start.

Kerecis Challenges: Kerecis faced a challenging quarter, delivering only 10% organic growth with an EBIT margin of just 1%, primarily due to significant sales disruptions from new Medicare reimbursement policies in the outpatient setting. This has led to decreased confidence and order placement among customers, resulting in negative growth in this segment.

Inpatient vs Outpatient Dynamics: While Kerecis is expected to see long-term benefits from fewer competitors in the outpatient segment, currently, they are faced with hesitancy from healthcare providers to make larger orders. The inpatient segment’s performance remains strong, backed by clinical efficacy, with double-digit growth anticipated, suggesting a potential offset to the outpatient decline.